Logo Volv Global
Contact
What we do

We find more of the right patients

Volv Global’s inTrigue machine learning technology identifies undiagnosed and misdiagnosed patients across population scale electronic health records (EHRs) and real world data (RWD). This allows us to uncover more people living with a disease beyond those already diagnosed, ensuring that no patient is left unseen.

By finding these hidden patient populations, we help people with rare and difficult to diagnose diseases gain access to the right treatment earlier. At the same time, we significantly expand the pool of high quality real world evidence available to accelerate clinical research, drive innovation in precision medicine, and support the development of new therapeutics.

Portrait of a confident older man with glasses in a striped shirt

Why accurate diagnosis matters

The importance of diagnosing the undiagnosed and the misdiagnosed

In today’s vast sea of medical data, many patients remain undiagnosed or misdiagnosed, leading to delayed treatments, wasted healthcare resources, and poor health outcomes. By leveraging AI driven patient identification and real world data (RWD), Volv Global ensures that overlooked patients receive the right care faster, more accurately, and at a lower cost.

Find the
right patients

Undiagnosed patients face unnecessary suffering, while misdiagnosed patients often receive inappropriate treatments. Accurate diagnosis ensures precision medicine by matching the right treatment to the right patient.

Optimise the
patient journey

Incorrect diagnoses lead to the wrong tests, treatments, and years of suffering. Our approach helps streamline healthcare pathways, reducing wasted expenses and improving patient outcomes.

Find more
patients

Accurately identifying entire disease cohorts improves clinical trial recruitment, rare disease research, and real world evidence generation, creating better insights for the entire healthcare ecosystem.

Volv Global powers solutions across stakeholders

Impact across the product lifecycle​

Clinical
Development

Expand the pool of patients for clinical trial recruitment by identifying undiagnosed and misdiagnosed patients. Our AI-driven approach improves trial design, recruitment speed, and real-world evidence generation.

Value, Access
& HEOR

Gain a wider, more accurate picture of the patient journey and treatment outcomes. Generate health economics and outcomes research (HEOR) insights supported by robust real-world data (RWD).

Medical
Affairs

Discover a more precise picture of patients, including biomarkers, phenotypes, and clinical features, to enhance diagnostic capability and support evidence-based medical communication.

Commercial
Excellence

Target patients more effectively with data-driven population insights, enabling market access strategies, earlier diagnosis, and stronger product lifecycle performance.

Close-up portrait of a bald man with a grey beard smiling gently

Industry-leading technology at work

How inTrigue finds more patients

inTrigue harnesses artificial intelligence (AI) and machine learning (ML) to analyse large-scale electronic health records (EHRs), claims data, and real-world evidence (RWE). By detecting hidden patient patterns that might otherwise remain undiagnosed, our platform delivers a comprehensive view of rare and difficult-to-diagnose diseases. This empowers providers and pharmaceutical companies to deliver earlier, more accurate, and more targeted interventions.

  • AI-Driven Patient Identification: scans vast medical datasets to detect previously overlooked or misdiagnosed patient segments.
  • Integrated Real-World Evidence (RWE): merges clinical, claims, and healthcare data for a holistic patient journey assessment.
  • Targeted Patient Engagement: supports personalised treatments and helps pharmaceutical companies accelerate clinical trial recruitment and streamline development.
Find out more

Transforming Rare Disease Diagnosis with AI

The millions of patients who remain undiagnosed or misdiagnosed every year, especially in the field of rare diseases. This , creates significant challenges for clinicians, pharmaceutical companies, and healthcare systems.

Volv Global’s inTrigue platform bridges this gap by combining AI, machine learning, and real-world data (RWD) to:

  • Accelerate rare disease detection– identify subtle patterns in patient records years before conventional methods.
  • Support precision medicine– enable personalised treatment pathways based on biomarker and phenotype insights.
  • Improve clinical trial efficiency– expand the patient pool with correctly identified candidates, reducing time-to-recruitment.
  • Enhance healthcare outcomes– shorten the diagnostic odyssey for patients while reducing costs for healthcare systems.

 

Explore our case studies to see how we’re already helping pharmaceutical innovators find more patients, faster.

 

Shaping the future today

Real-world impact​​

Unlocking the Future of Type 1 Diabetes Care: Why Earlier Diagnosis Must Match Innovation in Treatment

News Article: AI in healthcare

Webinar: How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: a case study

Beyond Quick Fixes: How Predictive Modelling Can Redefine Clinical Trial Enrolment

Beyond Initial Treatment: Navigating Recurrence Risk and Clinical Decisions in Cancer Survivors

Unlocking the Full Impact of Breakthrough Therapies in Breast Cancer Through Earlier Detection

Progressive Pulmonary Fibrosis: Solving the Puzzle of Poor Disease Control

Unlocking the Power of EMR Data for Earlier Gastric Cancer Diagnosis and Risk Prediction

Poster: Alpha-1 Antitrypsin Deficiency: Why millions remain undiagnosed

Finding Patients for Rare Diseases: A Case Study

Case Study: Detecting signs of Fabry and Pompe disease in UK clinical data

White Paper: The Path to Rare Disease Clinical Trial Innovation

What people ask

Frequently Asked Questions

inTrigue uses advanced AI and machine learning algorithms to analyse population-scale electronic health records (EHRs), claims data, and real-world evidence (RWE). By detecting subtle patterns in biomarkers, symptoms, and patient journeys, it identifies individuals who may be undiagnosed or misdiagnosed.

Many rare disease patients face years of misdiagnosis or no diagnosis at all. Accurate identification helps shorten the diagnostic odyssey, ensures patients receive the right treatment sooner, and improves clinical trial recruitment for new therapies.

We help pharmaceutical innovators expand their patient pools for clinical trials, generate more reliable real-world data (RWD), and improve health economics and outcomes research (HEOR). This leads to faster drug development, improved market access, and stronger evidence for value demonstration.

Yes. By reducing misdiagnoses and late diagnoses, inTrigue optimises resource allocation, lowers wasted healthcare costs, and improves patient outcomes. Healthcare providers can deliver more precise, cost-effective care with fewer delays.

Unlike generic solutions, Volv Global specialises in rare and difficult-to-diagnose diseases. Our proprietary AI models are built on decades of expertise, published research, and billions of health data points, making our insights highly reliable and actionable.

Logo Volv Global

How we help you

inTrigue

What we do

Insights

Meet Volv Global

inTrigue

Meet Volv Global